Page 281 - 2021_04-Haematologica-web

Letters to the Editor
1INSERM, UMR 976, Institut de Recherche Saint-Louis, Université de Paris and 2Immuno-Hematology, Saint-Louis Hospital, Paris, France.
Correspondence:
JEAN-CHRISTOPHE BORIES - jean-christophe.bories@inserm.fr
doi:10.3324/haematol.2019.242453
Disclosures: AA has received funds from Servier. Some of the work described in this letter is covered by a patent (international patent appli- cation number PCT/EP2020/070057).
Contributions: MF, CM-C and JCB designed the study; MF and CM-C performed all the experiments; AB provided the anti-CD38 hybridoma; AA and NR contributed to the functional assay; EN and CC performed the mouse studies; AT, JPF and BA provided samples from patients with multiple myeloma; MF, CM-C and JCB interpreted the data, designed the figures, and drafted the manuscript.
Acknowledgments: we thank M. Goodhardt, and D. Garrick
for their critique of the manuscript. We are also grateful to the animal facility and to the pole of cytometry of the “Institut de Recherche Saint-Louis” for technical help.
Funding: this work was supported by grants from the “Cancéropole Ile de France” and from the “Fondation Française pour la Recherche contre le Myélome et les Gammapathies monoclonales”. MF and CM-C were supported by fellowships from the French “Agence National pour la Recherche”, programme d’Investissements d’avenir (ANR-10-IDEX-03-02). MF was also supported by a fellowship from the “Société Française d’Hématologie”. AA was supported by a fellowship from the “Agence Nationale pour la Recherche Scientifique, CIFRE” in partnership with Servier.
References
1. Usmani SZ, Weiss BM, Plesner T, et al. Clinical efficacy of daratu- mumab monotherapy in patients with heavily pretreated relapsed
or refractory multiple myeloma. Blood. 2016;128(1):37-44.
2. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, lenalido- mide, and dexamethasone for multiple myeloma. N Engl J Med.
2016;375(14):1319-1331.
3. Palumbo A, Chanan-Khan A, Weisel K, et al. Daratumumab, borte-
zomib, and dexamethasone for multiple myeloma. N Engl J Med.
2016;375(8):754-766.
4. van de Donk N, Usmani SZ. CD38 antibodies in multiple myeloma:
mechanisms of action and modes of resistance. Front Immunol.
2018;9:2134.
5. Bannas P, Hambach J, Koch-Nolte F. Nanobodies and nanobody-
based human heavy chain antibodies as antitumor therapeutics.
Front Immunol. 2017;8:1603.
6. Brischwein K, Schlereth B, Guller B, et al. MT110: a novel bispecific
single-chain antibody construct with high efficacy in eradicating
established tumors. Mol Immunol. 2006;43(8):1129-1143.
7. Hipp S, Tai YT, Blanset D, et al. A novel BCMA/CD3 bispecific T- cell engager for the treatment of multiple myeloma induces selective
lysis in vitro and in vivo. Leukemia. 2017;31(10):2278.
8. Li J, Stagg NJ, Johnston J, et al. Membrane-proximal epitope facili- tates efficient T cell synapse formation by anti-FcRH5/CD3 and Is a requirement for myeloma cell killing. Cancer Cell. 2017;31(3):383-
395.
9. Seckinger A, Delgado JA, Moser S, et al. Target expression, genera-
tion, preclinical activity, and pharmacokinetics of the BCMA-T cell bispecific antibody EM801 for multiple myeloma treatment. Cancer Cell. 2017;31(3):396-410.
10.Ise T, Nagata S, Kreitman RJ, et al. Elevation of soluble CD307 (IRTA2/FcRH5) protein in the blood and expression on malignant cells of patients with multiple myeloma, chronic lymphocytic leukemia, and mantle cell lymphoma. Leukemia. 2007;21(1):169- 174.
11. Sanchez E, Li M, Kitto A, et al. Serum B-cell maturation antigen is elevated in multiple myeloma and correlates with disease status and survival. Br J Haematol. 2012;158(6):727-738.
12. Zuch de Zafra CL, Fajardo F, Zhong W, et al. Targeting multiple myeloma with AMG 424, a novel anti-CD38/CD3 bispecific T-cell- recruiting antibody optimized for cytotoxicity and cytokine release. Clin Cancer Res. 2019;25(13):3921-3933.
haematologica | 2021; 106(4)
1197